RGNX - REGENXBIO Inc.
| Previous Close | 39.42 |
| Open | 39.49 |
| Bid | 37.50 x 900 |
| Ask | 45.00 x 2200 |
| Day's Range | 39.04 - 40.20 |
| 52 Week Range | 30.38 - 78.15 |
| Volume | 420,957 |
| Avg. Volume | 564,982 |
| Market Cap | 1.469B |
| Beta (3Y Monthly) | 1.39 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.36 |
| Earnings Date | Nov 5, 2019 - Nov 11, 2019 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 83.00 |
- Simply Wall St.
An Intrinsic Calculation For REGENXBIO Inc. (NASDAQ:RGNX) Suggests It's 21% Undervalued
Does the September share price for REGENXBIO Inc. (NASDAQ:RGNX) reflect what it's really worth? Today, we will...
- Zacks
REGENXBIO (RGNX) Catches Eye: Stock Jumps 5.8%
REGENXBIO (RGNX) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
- Zacks
Ultragenyx-GeneTx Get Orphan Drug Status for GTX-102 From FDA
The FDA grants Orphan Drug and Rare Pediatric Disease designations to Ultragenyx (RARE) and partner GeneTx Biotherapeutics' GTX-102 for the treatment of Angelman Syndrome.
- Motley Fool
3 Top Biotech Stocks to Buy Right Now
Patent cliffs and pipeline risks are among the reasons these biologic drug specialists are attractively priced today.
- Zacks
Ultragenyx (RARE) Focuses on Pipeline Amid Low Revenues
Ultragenyx (RARE) focuses on the development of pipeline candidates. Being a new commercial company with lower revenues, development or regulatory setbacks could result in higher operating expenses.
- Thomson Reuters StreetEvents
Edited Transcript of RGNX earnings conference call or presentation 7-Aug-19 8:30pm GMT
Q2 2019 Regenxbio Inc Earnings Call
Motley FoolRegenxbio Inc. (RGNX) Q2 2019 Earnings Call Transcript
RGNX earnings call for the period ending June 30, 2019.
- Zacks
Regenxbio (RGNX) Reports Q2 Loss, Misses Revenue Estimates
Regenxbio (RGNX) delivered earnings and revenue surprises of -44.00% and -65.15%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?
- Simply Wall St.
Is REGENXBIO Inc.'s (NASDAQ:RGNX) CEO Overpaid Relative To Its Peers?
Ken Mills has been the CEO of REGENXBIO Inc. (NASDAQ:RGNX) since 2009. This report will, first, examine the CEO...
- Zacks
Are Options Traders Betting on a Big Move in REGENXBIO (RGNX) Stock?
Investors need to pay close attention to REGENXBIO (RGNX) stock based on the movements in the options market lately.
- Thomson Reuters StreetEvents
Edited Transcript of RGNX earnings conference call or presentation 7-May-19 8:30pm GMT
Q1 2019 Regenxbio Inc Earnings Call
- Zacks
REGENXBIO (RGNX) Catches Eye: Stock Jumps 7.4%
REGENXBIO (RGNX) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.
- Motley Fool
Approval of a Game-Changing Gene Therapy for SMA Delivers a Win for Novartis and Regenxbio
A $2.1 million price tag could make Zolgensma a blockbuster medicine for these companies.
Motley FoolRegenxbio Inc. (RGNX) Q1 2019 Earnings Call Transcript
RGNX earnings call for the period ending March 31, 2019.
- Motley Fool
Top Gene-Sequencing Stocks for 2019
These next-generation companies are working on game-changing ways to obtain and profit from genetic insight.
- Simply Wall St.
Did The Underlying Business Drive REGENXBIO's (NASDAQ:RGNX) Lovely 384% Share Price Gain?
We think that it's fair to say that the possibility of finding fantastic multi-year winners is what motivates many investors. Mistakes are inevitable, but a single top stock pick can cover any losses, and so much more. F...
- Zacks
4 Gene Therapy Players Likely to Become Buyout Targets in 2019
Gene therapy continues to be in focus given the recent spate of deals and acquisitions. We highlight four stocks, which have promising gene therapy candidates in their pipeline.
- Motley Fool
3 Small-Cap Biotech Stocks to Watch Now
These under-the-radar stocks could be poised to make big moves in the coming months.
- GlobeNewswire
New Research Coverage Highlights UnitedHealth Group, Ultragenyx Pharmaceutical, Navistar International, REGENXBIO, Par Pacific, and Athenex — Consolidated Revenues, Company Growth, and Expectations for 2019
NEW YORK, March 26, 2019 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Motley Fool
Gene Therapy M&A Has Shares Skyrocketing -- Could This Company Be Next?
Roche and Biogen are spending big bucks on gene therapy biotech stocks.
- Zacks
REGENXBIO (RGNX) in Focus: Stock Moves 5.1% Higher
REGENXBIO (RGNX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
- Motley Fool
3 Top Small-Cap Stocks to Buy Right Now
These three small-cap stocks have outstanding growth potential.
- Thomson Reuters StreetEvents
Edited Transcript of RGNX earnings conference call or presentation 27-Feb-19 9:30pm GMT
Q4 2018 Regenxbio Inc Earnings Call
Motley FoolRegenxbio Inc. (RGNX) Q4 2018 Earnings Conference Call Transcript
RGNX earnings call for the period ending December 31, 2018.
